(Q34204648)

31 July 2017

1 reference

title

Lipid-based amphotericin B: a review of the last 10 years of use. (English)

1 reference

31 July 2017

1 reference

Hann IM

1

1 reference

31 July 2017

Prentice HG

series ordinal

2

1 reference

31 July 2017

publication date

1 March 2001

1 reference

International Journal of Antimicrobial Agents

31 July 2017

published in

1 reference

31 July 2017

volume

17

1 reference

31 July 2017

issue

3

1 reference

31 July 2017

page(s)

161-169

1 reference

Diagnosis and prevention of fungal infection in the immunocompromized patient

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900341-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900341-1

7 January 2021

A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900341-1

7 January 2021

Clinical features and analysis of risk factors for invasive candidal infection after marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900341-1

7 January 2021

Progress in the diagnosis and management of aspergillosis in bone marrow transplantation: 13 years' experience.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900341-1

7 January 2021

Infectious complications in 126 patients treated with high-dose chemotherapy and autologous peripheral blood stem cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900341-1

7 January 2021

Surveillance tests for the diagnosis of invasive fungal infections in bone marrow transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900341-1

7 January 2021

Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900341-1

7 January 2021

Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900341-1

7 January 2021

Fluconazole versus amphotericin B as empirical antifungal therapy of unexplained fever in granulocytopenic cancer patients: a pragmatic, multicentre, prospective and randomised clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900341-1

7 January 2021

A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900341-1

7 January 2021

Antifungal agents. Part II. The azoles

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900341-1

7 January 2021

A controlled trial of the tolerance of amphotericin B infused in dextrose or in Intralipid in patients with haematological malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900341-1

7 January 2021

Reduced renal toxicity and improved clinical tolerance of amphotericin B mixed with intralipid compared with conventional amphotericin B in neutropenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900341-1

7 January 2021

Administration of lipid-emulsion versus conventional amphotericin B in patients with neutropenia

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900341-1

7 January 2021

Safety and toxicity of amphotericin B in glucose 5% or intralipid 20% in neutropenic patients with pneumonia or fever of unknown origin: randomised study

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900341-1

7 January 2021

Liposomal amphotericin B in the treatment of fungal infections in neutropenic patients: a single-centre experience of 133 episodes in 116 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900341-1

7 January 2021

Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900341-1

7 January 2021

Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900341-1

7 January 2021

Fungemia in the immunocompromised host. Changing patterns, antigenemia, high mortality

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900341-1

7 January 2021

Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900341-1

7 January 2021

A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900341-1

7 January 2021

Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900341-1

7 January 2021

Antifungal activity of elutriated human monocytes against Aspergillus fumigatus hyphae: enhancement by granulocyte-macrophage colony-stimulating factor and interferon-gamma

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900341-1

7 January 2021

A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900341-1

7 January 2021

Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900341-1

7 January 2021

An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900341-1

7 January 2021

Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900341-1

7 January 2021

Amphotericin B colloidal dispersion (Amphocil) vs fluconazole for the prevention of fungal infections in neutropenic patients: data of a prematurely stopped clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900341-1

7 January 2021

Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: a randomised, double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900341-1

7 January 2021

Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900341-1

7 January 2021

Late effects of intensive treatment for acute myeloid leukemia and myelodysplasia in childhood.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900341-1

7 January 2021

Antifungal therapy in 'bone marrow failure'.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900341-1

7 January 2021

Diagnosis of invasive aspergillosis in bone marrow transplant recipients by polymerase chain reaction

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2800%2900341-1

7 January 2021

10.1016/S0924-8579(00)00341-1

Identifiers

DOI

1 reference

31 July 2017

1 reference